EASD 2026 Key Press Releases (October 2)
On the fifth and final day of EASD 2026, Hansoh Pharma presented results from its Ph3 olatorepatide (QW SC GLP-1/GIP dual agonist) LIGHTEN study in Chinese adults with overweight or obesity and ≥1 weight-related comorbidity (view press release; view CT.gov record). Below, FENIX provides highlights and insights from the results.
